30 research outputs found
Maternal demographic and clinical characteristics of patients diagnosed with an isolated short femur compared with controls.
<p><sup>1</sup>Student’s t-test</p><p><sup>2</sup>Chi-square test</p><p>SD: standard deviation, BMI: body mass index, FL: femur length</p><p>Maternal demographic and clinical characteristics of patients diagnosed with an isolated short femur compared with controls.</p
Perinatal outcome in fetuses with isolated short femur length compared with controls.
<p><sup>1</sup>Student’s t-test</p><p><sup>2</sup>Chi-square test</p><p>SD: standard deviation, SGA: small for gestational age, LBW: low birth weight, NICU: neonatal intensive care unit</p><p>Perinatal outcome in fetuses with isolated short femur length compared with controls.</p
Flowchart.
<p>The process of inclusion and exclusion of patients in order to find the sample of patients included in the present study (= 165).</p
Median duration of chemotherapy broken down by clinical and pathological parameters.
<p>Median duration of chemotherapy broken down by clinical and pathological parameters.</p
Survival curves.
<p>Kaplan Meier curves for patients stratified into risk groups according to the delay of total chemo-duration are given for progression-free (PFS), cancer-specific (CSS), and overall survival (OS) in figures A, B, and C, respectively. 5-year rates of PFS, CSS and OS for each risk group are given in the table below.</p
Hazard ratios of uni- and multivariable analyses for the association between delay of total chemo-duration and progression-free (PFS), cancer-specific (CSS), and overall survival (OS).
<p>Hazard ratios of uni- and multivariable analyses for the association between delay of total chemo-duration and progression-free (PFS), cancer-specific (CSS), and overall survival (OS).</p
Characteristics of 114 patients with primary metastatic breast cancer.
<p>HR = hormonal receptor (estrogen and/or progesterone receptor), GGT = gamma-glutamyltransferase, HER2 = human epidermal growth factor 2-receptor</p><p>Characteristics of 114 patients with primary metastatic breast cancer.</p
Univariate and multivariable overall-survival analyses.
<p><sup>a</sup>Kaplan—Meier analysis (log-rank test)</p><p><sup><b>b</b></sup>Multivariable Cox-regression analysis</p><p>*mean (SD) age: 61.0 (13.4) years; GGT = gamma-glutamyltransferase, HER2 = human epidermal growth factor 2-receptor, OS = overall survival, HR = hazard ratio, 95% CI = 95% Confidence Interval</p><p>Univariate and multivariable overall-survival analyses.</p
Pre-therapeutic GGT serum levels of patients with primary metastatic breast cancer broken down by clinical-pathological parameters.
<p>* One-way ANOVA</p><p><sup>+</sup> Student’s T-test</p><p><sup>⇞</sup> Values are given as mean (standard deviation), GGT = gamma-glutamyltransferase, HER2 = human epidermal growth factor 2-receptor, SD = standard deviation</p><p>Pre-therapeutic GGT serum levels of patients with primary metastatic breast cancer broken down by clinical-pathological parameters.</p